NCT Number: NCT00004784
Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
OBJECTIVES: I. Compare the effects of ursodiol (ursodeoxycholic acid), with and without methotrexate, on pruritus, incapacitation index, and serum markers of activity and severity in patients with primary biliary cirrhosis.
II. Compare the effects of these regimens on the development of ascites, encephalopathy, varices (or bleeding from pre-existing varices), histologic liver changes, transplantation, and survival.
III. Compare the toxicity and safety of each regimen.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–69 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution and Ludwig histologic stage.
All patients are treated with ursodiol (ursodeoxycholic acid, UDCA) for 6 months. If entry criteria continue to be met, patients are randomly assigned to UDCA/methotrexate or UDCA/placebo.
Combination therapy continues for at least 5 years.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- The following criteria must be met prior to study entry and ursodiol treatment: Bilirubin less than 3 mg/dL Alkaline phosphatase at least 1.5 times normal limits Albumin at least 3 g/dL The following criteria must be met prior to randomization to Arms I and II: Primary biliary cirrhosis (PBC), i.e.: Cholestatic liver disease for at least 6 months prior to randomization Liver biopsy compatible with PBC within 6 months prior to randomization No biliary obstruction on ultrasound, computerized tomography, or cholangiography The following exclude: Asymptomatic and stage I liver histology (Ludwig classification) Hepatic encephalopathy Ascites Variceal bleeding No liver disease of other etiology, e.g.: Chronic hepatitis B or C Autoimmune chronic active hepatitis Alcoholic liver disease Sclerosing cholangitis Drug-induced liver disease Symptomatic or obstructive gallstones --Prior/Concurrent Therapy-- At least 6 months since the following immunosuppressives: Cyclosporine Tacrolimus Methotrexate At least 3 months since other immunosuppressives, e.g.: Azathioprine Chlorambucil Colchicine Corticosteroids Penicillamine At least 3 months since rifampin --Patient Characteristics-- Life expectancy: No major illness limiting life span Hematopoietic: WBC at least 2500/mm3 Absolute granulocyte count at least 1500/mm3 Platelet count at least 80,000/mm3 Hepatic: See Disease Characteristics Renal: Creatinine clearance at least 60 mL/min Pulmonary: No diffusion capacity or vital capacity less than 50% of predicted Other: Antimitochondrial antibody positive HIV antibody negative No alcoholism within the past 2 years No epilepsy requiring phenytoin No malignancy within the past 5 years other than skin cancer No pregnant women Adequate contraception required of fertile patients
Treatment and study plan
ursodiol
DrugSponsors and collaborators
Lead sponsor
National Center for Research Resources (NCRR)
Nih
Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Texas
Registry information
Important dates
- Study start
- 1994
- First posted
- Feb 25, 2000
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
NCT00004842
Bile Duct Diseases, Biliary Tract Diseases
Rochester, Minnesota, United States
View Trial DetailsLow-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis
NCT00004748
Bile Duct Diseases, Biliary Tract Diseases
View Trial DetailsTrial of Psychoeducational and Hypnosis Interventions on the Fatigue Associated With PBC in Women
NCT03630718
Bile Duct Diseases, Biliary Tract Diseases
Paris, France
View Trial DetailsAutologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
NCT03468699
Bile Duct Diseases, Biliary Atresia
Hanoi, Vietnam
View Trial Details